Patents by Inventor Donald Landry

Donald Landry has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • IDENTIFICATION OF COMPOUNDS THAT INHIBIT STRESS GRANULE FORMATION AND TAU AGGREGATION BY TARGETING TIAI
    Publication number: 20220332689
    Abstract: This invention provides a method of ameliorating the symptoms of, or treating a neurodegenerative disorder, Welander distal myopathy, psychiatric illness, or cancer in a mammal, the method comprising administering to the mammal an effective amount of a compound that decreases TIA1-dependent stress granule formation.
    Type: Application
    Filed: September 16, 2020
    Publication date: October 20, 2022
    Inventors: Joseph B. RAYMAN, Donald LANDRY, Shixian DENG
  • Activators of autophagic flux and phospholipase d and clearance of protein aggregates including tau and treatment of proteinopathies
    Patent number: 11261199
    Abstract: The present application discloses compounds which are activators of autophagic flux and pharmaceutical compositions comprising said activators. It further discloses use of said compounds and pharmaceutical compositions in the treatment of neurodegenerative diseases, particularly proteinopathies and tauopathies such as Alzheimer's disease. It further discloses methods of enhancing autophagic flux.
    Type: Grant
    Filed: March 13, 2020
    Date of Patent: March 1, 2022
    Assignees: The Trustees of Columbia University in the City of New York, NY State Psychiatric Institute
    Inventors: Kirsten Alison Rinderspacher, Wai Yu, Karen Duff, Donald Landry, Shi-Xian Deng
  • Activators of autophagic flux and phospholipase D and clearance of protein aggregates including tau and treatment of proteinopathies
    Patent number: 11230558
    Abstract: The present application discloses compounds which are activators of autophagic flux and pharmaceutical compositions comprising said activators. It further discloses use of said compounds and pharmaceutical compositions in the treatment of neurodegenerative diseases, particularly proteinopathies and tauopathies such as Alzheimer's disease. It further discloses methods of enhancing autophagic flux.
    Type: Grant
    Filed: July 5, 2018
    Date of Patent: January 25, 2022
    Assignees: The Trustees of Columbia University in the City of New York, NY State Psychiatric Institute
    Inventors: Kirsten Alison Rinderspacher, Wai Yu, Karen Duff, Donald Landry, Shi-Xian Deng
  • Mutants of cocaine esterase
    Patent number: 11098296
    Abstract: Provided are mutant cocaine esterase polypeptides and PEGylated formulations thereof.
    Type: Grant
    Filed: December 21, 2018
    Date of Patent: August 24, 2021
    Assignees: The Trustees of Columbia University in the City of New York, University of Kentucky Research Foundation
    Inventors: Donald Landry, Chang-Guo Zhan
  • Activators of autophagic flux and phospholipase D and clearance of protein aggregates including tau and treatment of proteinopathies
    Patent number: 11008341
    Abstract: The present application discloses compounds which are activators of autophagic flux and pharmaceutical compositions comprising said activators. It further discloses use of said compounds and pharmaceutical compositions in the treatment of neurodegenerative diseases, particularly proteinopathies and tauopathies such as Alzheimer's disease. It further discloses methods of enhancing autophagic flux.
    Type: Grant
    Filed: July 5, 2018
    Date of Patent: May 18, 2021
    Assignees: The Trustees of Columbia University in the City of New York, NY State Psychiatric Institute
    Inventors: Kirsten Alison Rinderspacher, Wai Yu, Karen Duff, Donald Landry, Shi-Xian Deng
  • Activators of autophagic flux and phospholipase D and clearance of protein aggregates including tau and treatment of proteinopathies
    Patent number: 10865214
    Abstract: The present application discloses compounds which are activators of autophagic flux and pharmaceutical compositions comprising said activators. It further discloses use of said compounds and pharmaceutical compositions in the treatment of neurodegenerative diseases, particularly proteinopathies and tauopathies such as Alzheimer's disease. It further discloses methods of enhancing autophagic flux.
    Type: Grant
    Filed: July 5, 2018
    Date of Patent: December 15, 2020
    Assignees: The Trustees of Columbia University in they City of New York, NY State Psychiatric Institute
    Inventors: Kirsten Alison Rinderspacher, Wai Yu, Karen Duff, Donald Landry, Shi-Xian Deng
  • ACTIVATORS OF AUTOPHAGIC FLUX AND PHOSPHOLIPASE D AND CLEARANCE OF PROTEIN AGGREGATES INCLUDING TAU AND TREATMENT OF PROTEINOPATHIES
    Publication number: 20200216469
    Abstract: The present application discloses compounds which are activators of autophagic flux and pharmaceutical compositions comprising said activators. It further discloses use of said compounds and pharmaceutical compositions in the treatment of neurodegenerative diseases, particularly proteinopathies and tauopathies such as Alzheimer's disease. It further discloses methods of enhancing autophagic flux.
    Type: Application
    Filed: March 13, 2020
    Publication date: July 9, 2020
    Inventors: Kirsten Alison Rinderspacher, Wai Yu, Karen Duff, Donald Landry, Shi-Xian Deng
  • Activators of autophagic flux and phospholipase D and clearance of protein aggregates including tau and treatment of proteinopathies
    Patent number: 10626124
    Abstract: The present application discloses compounds which are activators of autophagic flux and pharmaceutical compositions comprising said activators. It further discloses use of said compounds and pharmaceutical compositions in the treatment of neurodegenerative diseases, particularly proteinopathies and tauopathies such as Alzheimer's disease. It further discloses methods of enhancing autophagic flux.
    Type: Grant
    Filed: July 5, 2018
    Date of Patent: April 21, 2020
    Assignees: The Trustees of Columbia University in the City of New York, NY State Psychiatric Institute
    Inventors: Kirsten Alison Rinderspacher, Wai Yu, Karen Duff, Donald Landry, Shi-Xian Deng
  • Activators of autophagic flux and phospholipase D and clearance of protein aggregates including tau and treatment of proteinopathies
    Patent number: 10487091
    Abstract: The present application discloses compounds which are activators of autophagic flux and pharmaceutical compositions comprising said activators. It further discloses use of said compounds and pharmaceutical compositions in the treatment of neurodegenerative diseases, particularly proteinopathies and tauopathies such as Alzheimer's disease. It further discloses methods of enhancing autophagic flux.
    Type: Grant
    Filed: April 5, 2017
    Date of Patent: November 26, 2019
    Assignees: The Trustees of Columbia University in the City of New York, NY State Psychiatric Institute
    Inventors: Kirsten Alison Rinderspacher, Wai Yu, Karen Duff, Donald Landry, Shi-Xian Deng
  • MUTANTS OF COCAINE ESTERASE
    Publication number: 20190352625
    Abstract: Provided are mutant cocaine esterase polypeptides and PEGylated formulations thereof.
    Type: Application
    Filed: December 21, 2018
    Publication date: November 21, 2019
    Inventors: Donald Landry, Chang-Guo Zhan
  • ACTIVATORS OF AUTOPHAGIC FLUX AND PHOSPHOLIPASE D AND CLEARANCE OF PROTEIN AGGREGATES INCLUDING TAU AND TREATMENT OF PROTEINOPATHIES
    Publication number: 20190112317
    Abstract: The present application discloses compounds which are activators of autophagic flux and pharmaceutical compositions comprising said activators. It further discloses use of said compounds and pharmaceutical compositions in the treatment of neurodegenerative diseases, particularly proteinopathies and tauopathies such as Alzheimer's disease. It further discloses methods of enhancing autophagic flux.
    Type: Application
    Filed: October 5, 2016
    Publication date: April 18, 2019
    Inventors: Kirsten Alison Rinderspacher, Wai Yu, Karen Duff, Donald Landry, Shi-Xian Deng
  • Mutants of cocaine esterase
    Patent number: 10160960
    Abstract: Provided are mutant cocaine esterase polypeptides and PEGylated formulations thereof.
    Type: Grant
    Filed: August 6, 2014
    Date of Patent: December 25, 2018
    Assignee: The Trustees of Columbia University in the City of New York
    Inventors: Donald Landry, Chang-Guo Zhan
  • ACTIVATORS OF AUTOPHAGIC FLUX AND PHOSPHOLIPASE D AND CLEARANCE OF PROTEIN AGGREGATES INCLUDING TAU AND TREATMENT OF PROTEINOPATHIES
    Publication number: 20180319818
    Abstract: The present application discloses compounds which are activators of autophagic flux and pharmaceutical compositions comprising said activators. It further discloses use of said compounds and pharmaceutical compositions in the treatment of neurodegenerative diseases, particularly proteinopathies and tauopathies such as Alzheimer's disease. It further discloses methods of enhancing autophagic flux.
    Type: Application
    Filed: July 5, 2018
    Publication date: November 8, 2018
    Inventors: Kirsten Alison Rinderspacher, Wai Yu, Karen Duff, Donald Landry, Shi-Xian Deng
  • ACTIVATORS OF AUTOPHAGIC FLUX AND PHOSPHOLIPASE D AND CLEARANCE OF PROTEIN AGGREGATES INCLUDING TAU AND TREATMENT OF PROTEINOPATHIES
    Publication number: 20180312527
    Abstract: The present application discloses compounds which are activators of autophagic flux and pharmaceutical compositions comprising said activators. It further discloses use of said compounds and pharmaceutical compositions in the treatment of neurodegenerative diseases, particularly proteinopathies and tauopathies such as Alzheimer's disease. It further discloses methods of enhancing autophagic flux.
    Type: Application
    Filed: July 5, 2018
    Publication date: November 1, 2018
    Inventors: Kirsten Alison Rinderspacher, Wai Yu, Karen Duff, Donald Landry, Shi-Xian Deng
  • ACTIVATORS OF AUTOPHAGIC FLUX AND PHOSPHOLIPASE D AND CLEARANCE OF PROTEIN AGGREGATES INCLUDING TAU AND TREATMENT OF PROTEINOPATHIES
    Publication number: 20180312526
    Abstract: The present application discloses compounds which are activators of autophagic flux and pharmaceutical compositions comprising said activators. It further discloses use of said compounds and pharmaceutical compositions in the treatment of neurodegenerative diseases, particularly proteinopathies and tauopathies such as Alzheimer's disease. It further discloses methods of enhancing autophagic flux.
    Type: Application
    Filed: July 5, 2018
    Publication date: November 1, 2018
    Inventors: Kirsten Alison Rinderspacher, Wai Yu, Karen Duff, Donald Landry, Shi-Xian Deng
  • SK AND IK CHANNEL AGONISTS FOR TREATMENT OF HEART FAILURE
    Publication number: 20180118699
    Abstract: The present invention provides compounds that are improved potassium channel agonists. Pharmaceutical compositions including a pharmaceutically acceptable carrier and a compound of the present invention are also provided. Methods and kits for treating or ameliorating the effects of heart failure syndrome, high blood pressure and diabetes also are provided. Methods, kits and compositions which include compounds of the present invention also are provided.
    Type: Application
    Filed: November 21, 2017
    Publication date: May 3, 2018
    Inventors: Steven MARX, Elaine WAN, Donald LANDRY, Sergey SAKHAROV, Guoxia LIU, Shi-Xian DENG, Xiaoming XU
  • ACTIVATORS OF AUTOPHAGIC FLUX AND PHOSPHOLIPASE D AND CLEARANCE OF PROTEIN AGGREGATES INCLUDING TAU AND TREATMENT OF PROTEINOPATHIES
    Publication number: 20170210759
    Abstract: The present application discloses compounds which are activators of autophagic flux and pharmaceutical compositions comprising said activators. It further discloses use of said compounds and pharmaceutical compositions in the treatment of neurodegenerative diseases, particularly proteinopathies and tauopathies such as Alzheimer's disease. It further discloses methods of enhancing autophagic flux.
    Type: Application
    Filed: April 5, 2017
    Publication date: July 27, 2017
    Inventors: Kirsten Alison Rinderspacher, Wai Yu, Karen Duff, Donald Landry, Shi-Xian Deng
  • Process for preparing benzothiazepines from gamma-aminoalkylbenzenes
    Patent number: 9573914
    Abstract: The invention provides a process for preparing a 2,3,4,5-tetrahydro[1,4]benzothiazepine of formula: by reacting a [2-(acylaminoethyl)thio]arene of formula with an aldehyde or a multimer thereof, and with an acid. The invention also provides for first reacting the [2-(acylaminoethyl)thio]arene with the aldehyde or multimer thereof and a base to form an [N-hydroxymethyl-2-[acylaminoethyl)thio]arene of formula then treating the [N-hydroxymethyl-2-(acylaminoethyl)thio]arene with the acid to form the 2,3,4,5-tetrahydro[1,4]benzothiazepine.
    Type: Grant
    Filed: December 23, 2013
    Date of Patent: February 21, 2017
    Assignees: LES LABORATOIRES SERVIER, ARMGO Pharma, Inc.
    Inventors: Shixian Deng, Sandro Belvedere, Jiaming Yan, Donald Landry
  • GLUCOSE METABOLISM MODULATING COMPOUNDS
    Publication number: 20160311773
    Abstract: The present invention provides, inter alia, dihydropyridone compounds and compositions, including analogs of a vesicular monoamine transporter type 2 (VMAT2) antagonist. The present invention also provides methods of using such compounds/analogs for modulating glucose levels, and/or preventing, treating, or ameliorating the effects of diabetes and hyperglycemia.
    Type: Application
    Filed: April 20, 2015
    Publication date: October 27, 2016
    Inventors: Paul Harris, Antonella Maffei, Yuli Xie, Donald Landry
  • MUTANTS OF COCAINE ESTERASE
    Publication number: 20160177277
    Abstract: Provided are mutant cocaine esterase polypeptides and PEGylated formulations thereof.
    Type: Application
    Filed: August 6, 2014
    Publication date: June 23, 2016
    Applicant: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
    Inventors: Donald Landry, Chang-Guo Zhan